RecruitingPhase 1NCT03065335

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder


Sponsor

National Institute of Mental Health (NIMH)

Enrollment

150 participants

Start Date

May 25, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objective: Main Study: To study the effects of ketamine in treating depression. Ketamine Metabolites Substudy: To study how ketamine effects brain chemistry. To study how ketamine effects the brain. This is done by looking at metabolites, which are created when a drug is broken down. Eligibility: Main Study: People ages 18-65 with major depressive disorder and healthy volunteers Ketamine Metabolites Substudy: Healthy volunteers ages 18-65 Design: Main Study: Participants will be screened in another study, with: * Medical and psychiatric history * Psychiatric and physical exam * Blood, urine, and heart tests Participants will be inpatients at NIH for 4 phases totaling 14-20 weeks. Phase I (2-7 weeks): * Gradually stop current medications * MRI: Participants lie and perform tasks in a machine that takes pictures of the body. * Mood and thinking tests * Blood and urine tests * Sleep test: Monitors on the skin record brain waves, breathing, heart rate, and movement during sleep. * Transcranial magnetic stimulation: A coil on the scalp gives an electrical current that affects brain activity. * Stress tests: Electrodes on the skin measure reactions to loud noises or electric shocks. Phase I tests are repeated in Phases II and III and in the final visit. Phase II (4-5 weeks): * 4 weekly IV infusions of ketamine or a placebo during an MRI or MEG. For the MEG, a cone over the head records brain activity. Phase III (optional): * 8 infusions of ketamine over 4 weeks Phase IV (optional): * Symptoms monitoring for 4 weeks * Participants will have a final visit. They will be offered standard treatment at NIH for up to 2 months. Ketamine Metabolites Substudy: Participants will be screened in another study, with: * Medical and psychiatric history * Psychiatric and physical exam * Blood, urine, and heart tests Participants will be inpatients at NIH for 4 days. Study Procedures: Mood and thinking tests Blood and urine tests 1 infusion of ketamine Spinal tap and spinal catheter: Used to get samples of cerebrospinal fluid (CSF). This is a fluid that moves around and within the brain and spinal cord. Studying CSF will help us learn how ketamine effects brain chemistry


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study uses brain imaging and other biological measurements to understand how ketamine infusions work in the brain and whether they can provide lasting relief from severe depression that has not responded to other treatments. **You may be eligible if...** - You are between 18 and 65 years old - You have major depressive disorder (MDD) with a current episode lasting at least 2 weeks and a high depression score on a standardized rating scale - Your depression has not responded to at least one adequate antidepressant treatment in the past - You are willing to be hospitalized during the study - You have already been evaluated through a related NIH screening protocol **You may NOT be eligible if...** - You have bipolar disorder, schizophrenia, or another psychotic disorder - You have used drugs or alcohol heavily within the past 3 months - You are pregnant, breastfeeding, or unwilling to use contraception - You have serious heart, liver, kidney, lung, or neurological disease - You have a history of seizures or epilepsy - You have taken opioid medication in the past 3 months - You have a pacemaker or other metal implant that is incompatible with MRI - You weigh more than 119 kg (about 262 pounds) - You are HIV positive Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine

N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

OTHERPlacebo

Placebo comparator

DEVICECobot TS MV robotic arm for TMS

TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil

DEVICENeurOptics PLRTM-30000 Pupillometer

The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.


Locations(1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03065335


Related Trials